Duchenne Muscular Dystrophy (DMD) Pipeline Analysis Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals, Competitive Landscape | Capricor Therapeutics (CAP-1002), Santhera, Sarepta, Italfarmaco, FibroGen, Pfizer, Daiichi Sankyo

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 75+ key pharma and biotech companies are working on 75+ pipeline drugs in the Duchenne Muscular Dystrophy therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Duchenne Muscular Dystrophy Pipeline Insight" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Duchenne Muscular Dystrophy Therapeutics Market.

The report provides a detailed description of the Duchenne Muscular Dystrophy drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Duchenne Muscular Dystrophy Clinical Trial Activities and Regulatory Developments in the domain @
https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Duchenne Muscular Dystrophy Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Duchenne Muscular Dystrophy therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Duchenne Muscular Dystrophy treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Duchenne Muscular Dystrophy drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Duchenne Muscular Dystrophy treatment market.

Learn More about the Clinical and Commercial Development Activities in the Duchenne Muscular Dystrophy Therapeutics Domain @
https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Duchenne Muscular Dystrophy Therapeutics Analysis
Around 75+ prominent pharma and biotech companies are actively engaged in developing therapies for Duchenne Muscular Dystrophy (DMD), a progressive genetic disorder characterized by muscle degeneration and weakness. Among these, Roche stands out for having advanced DMD drug candidates in Phase III clinical trials, reflecting a significant milestone in the quest for effective treatments for this debilitating condition. This collective effort underscores the dedication of the pharmaceutical industry to address the urgent medical needs of individuals affected by DMD, offering hope for improved management and quality of life for patients and their families.

Duchenne Muscular Dystrophy Companies in the Therapeutics Market Include:
Some of the key companies in the Duchenne Muscular Dystrophy Market include Santhera Pharmaceuticals, Sarepta Therapeutics, Italfarmaco, Wave Life Sciences Ltd, FibroGen, Edgewise Therapeutics, Fordadistrogenemovaparvovec, Daiichi Sankyo, ENCell, Taiho Pharmaceutical, Solid Biosciences, Capricor, Nippon Shinyaku, Hansa Biopharma, PTC Therapeutics, Pfizer, ReveraGen BioPharma (formerly Santhera Pharmaceuticals), and Antisense Therapeutics, and others.

Emerging and Marketed Duchenne Muscular Dystrophy Therapies Covered in the Report Include:
• Amondys 45: Sarepta Therapeutics
• Emflaza: PTC Therapeutics
• Exondys 51: Sarepta Therapeutics
• Givinostat: Italfarmaco
• Pamrevlumab: Fibrogen
• PF-06939926: Pfizer
• Pizuglanstat (TAS-205): Taiho Pharmaceutical
• Translarna: PTC Therapeutics
• Vamorolone: Santhera Pharmaceuticals/ReveraGen BioPharma
• Viltepso: Nippon Shinyaku
• Vyondys 53 (Golodirsen): Sarepta Therapeutics
And Many More

Get an in-depth Assessment of the Emerging Therapies and Duchenne Muscular Dystrophy Companies Actively Working in the Market @
https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Emerging Duchenne Muscular Dystrophy Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued and inactive candidates

Route of Administration
Duchenne Muscular Dystrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous

Molecule Type
Products have been categorized under various Molecule types such as
• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Request for Sample PDF to Understand More About the Duchenne Muscular Dystrophy Treatment Outlook and Future Perspectives @
https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Duchenne Muscular Dystrophy Current Treatment Patterns
4. Duchenne Muscular Dystrophy - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Duchenne Muscular Dystrophy Late-Stage Products (Phase-III)
7. Duchenne Muscular Dystrophy Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Duchenne Muscular Dystrophy Discontinued Products
13. Duchenne Muscular Dystrophy Product Profiles
14. Duchenne Muscular Dystrophy Companies
15. Duchenne Muscular Dystrophy Drugs
16. Dormant and Discontinued Products
17. Duchenne Muscular Dystrophy Unmet Needs
18. Duchenne Muscular Dystrophy Future Perspectives
19. Duchenne Muscular Dystrophy Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings @
https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.